Salud financiera de hoja de balance de BIOLASE

Salud financiera controles de criterios 2/6

BIOLASE tiene un patrimonio de los accionistas total de $269.0K y una deuda total de $14.0M, lo que sitúa su ratio deuda-patrimonio en 5207.1%. Sus activos y pasivos totales son $34.4M y $34.1M respectivamente.

Información clave

5,207.1%

Ratio deuda-patrimonio

US$14.01m

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	US$6.39m
Patrimonio	US$269.00k
Total pasivo	US$34.08m
Activos totales	US$34.35m

Actualizaciones recientes sobre salud financiera

Recent updates

BIOLASE - Good News Across The Board But Still Only Suited For The Most Speculative Investors

Nov 24

Is BIOLASE (NASDAQ:BIOL) Using Debt Sensibly?

Jul 14

Biolase shares jump 11% after regaining Nasdaq compliance

Feb 04

Biolase: Business Recovery On The Way But Warrant Overhang Should Keep Investors Sidelined

Feb 01

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo ($25.0M) de BIOL superan a sus pasivos a corto plazo ($21.4M).

Pasivo a largo plazo: Los activos a corto plazo de BIOL ($25.0M) superan a sus pasivos a largo plazo ($12.7M).

Historial y análisis de deuda-patrimonio

Nivel de deuda: La relación deuda neta-capital de BIOL (2830.5%) se considera alta.

Reducción de la deuda: El ratio deuda-patrimonio de BIOL ha crecido de 156.4% a 5207.1% en los últimos 5 años.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: BIOL tiene menos de un año de cash runway basado en su flujo de caja libre actual.

Pronóstico de cash runway: BIOL tiene menos de un año de cash runway si el flujo de caja libre sigue reduciéndose a tasas históricas de 8.6% cada año

Salud financiera de hoja de balance de BIOLASE

Salud financiera controles de criterios 2/6

Información clave

Actualizaciones recientes sobre salud financiera

Nasdaq Hearings Panel Determines to Delist BIOLASE's Common Stock

Biolase Receives an Additional Staff Determination Letter from Nasdaq Regarding Non-Compliance with Minimum $2.5 Million Stockholders’ Equity Requirement for Continued Listing Set in Nasdaq Listing Rule 5550(b)

BIOLASE Receives Staff Determination Letter from Nasdaq Regarding Failure to Meet the Minimum Closing Bid Price Requirement as Required by Listing Rule 5550(a)(2)

BIOLASE Receives Non-Compliance Notice from Nasdaq Regarding Minimum Bid Price

Nasdaq Grants Extension to BIOLASE, Inc. to Regain Compliance with the Stockholders' Equity Continued Listing Requirement

BIOLASE Receives Non-Compliance Notice From Nasdaq

Recent updates

BIOLASE, Inc.(OTCPK:BIOL) dropped from NASDAQ Composite Index

Nasdaq Hearings Panel Determines to Delist BIOLASE's Common Stock

Biolase Receives an Additional Staff Determination Letter from Nasdaq Regarding Non-Compliance with Minimum $2.5 Million Stockholders’ Equity Requirement for Continued Listing Set in Nasdaq Listing Rule 5550(b)

BIOLASE, Inc. Reiterates Earnings Guidance for the Full-Year of 2024

BIOLASE, Inc. to Report Q1, 2024 Results on May 13, 2024

BIOLASE Receives Staff Determination Letter from Nasdaq Regarding Failure to Meet the Minimum Closing Bid Price Requirement as Required by Listing Rule 5550(a)(2)

BIOLASE, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2024

BIOLASE, Inc. to Report Q4, 2023 Results on Mar 21, 2024

BIOLASE, Inc., Annual General Meeting, May 02, 2024

BIOLASE Receives Non-Compliance Notice from Nasdaq Regarding Minimum Bid Price

BIOLASE, Inc. has completed a Composite Units Offering in the amount of $7.031795 million.

Nasdaq Grants Extension to BIOLASE, Inc. to Regain Compliance with the Stockholders' Equity Continued Listing Requirement

BIOLASE, Inc. Provides Earnings Guidance for the Full-Year 2023

BIOLASE, Inc. Provides Earnings Guidance for the Year 2024

Dr. Carol Gomez Summerhays Intends to Resign as Member of the Board of Directors of Biolase, Inc

BIOLASE, Inc. Successfully Concludes Waterlase iPlus All Tissue Laser Trial

BIOLASE, Inc. has filed a Follow-on Equity Offering.

BIOLASE Receives Non-Compliance Notice From Nasdaq

BIOLASE, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year of 2023

BIOLASE, Inc. Announces Study Performed by the Independent Mcguire Institute Confirms Positive 12 Month Clinical Outcomes for Biolase Repair(R) Perio Protocol

BIOLASE, Inc. to Report Q3, 2023 Results on Nov 09, 2023

BIOLASE, Inc. has completed a Composite Units Offering in the amount of $4.5 million.

BIOLASE Provides Non-Compliance Update

BIOLASE, Inc. Provides Earnings Guidance for the Second Half of 2023

BIOLASE, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Listing Qualifications Staff of Nasdaq Determines to Delist BIOLASE's Common Stock from the Nasdaq Capital Market and to Suspend Trading of the Common Stock at the Opening of Business on June 20 2023

BIOLASE, Inc. has completed a Composite Units Offering.

BIOLASE, Inc. has completed a Composite Units Offering.

BIOLASE, Inc. to Report Q1, 2023 Results on May 11, 2023

BIOLASE, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2022

BIOLASE Receives a Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market

BIOLASE, Inc. has completed a Follow-on Equity Offering in the amount of $9.635963 million.

BIOLASE, Inc. has completed a Follow-on Equity Offering in the amount of $9.635963 million.

PIPStek LLC Files Patent Infringement Lawsuit Against BIOLASE

BIOLASE, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year 2022

BIOLASE, Inc. to Report Q3, 2022 Results on Nov 10, 2022

BIOLASE, Inc. Appoints Russell Morrow as Chief Dental Officer, Effective November 1, 2022

Biolase partners with dental speciality programs across U.S.

BIOLASE, Inc. Provides Revenue Forecast for the Third Quarter Ending September 30, 2022 and Full Year of 2022

BIOLASE, Inc. Provides Revenue Forecast for the Third Quarter Ending September 30, 2022 and Full Year of 2022

BIOLASE, Inc. to Report Q2, 2022 Results on Aug 11, 2022

BIOLASE: Ongoing Operating Losses, Capital Raises To Sustain Liquidity

BIOLASE, Inc. Appoints Steven Sandor to Chief Operating Officer

BIOLASE amends senior secured term loan with SWK Funding

BIOLASE, Inc. Regains Compliance with Nasdaq Minimum Bid Price Requirement

BIOLASE, Inc. Provides Revenue Guidance for the Second Quarter and Full Year 2022

First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

High number of new directors

BIOLASE, Inc. Announces Election of Board of Directors

BIOLASE, Inc. to Report Q1, 2022 Results on May 12, 2022

BIOLASE: Bad News Across The Board - Sell

Price target decreased to US$2.13

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Is BIOLASE (NASDAQ:BIOL) Weighed On By Its Debt Load?

BIOLASE, Inc. Provides Revenue Guidance for the Fourth Quarter of 2021

BIOLASE - Speculative Buy After Strong Preliminary Q4 Results

BIOLASE and EdgeEndo Announce FDA 510(k) Clearance of New EdgePRO Laser-Assisted Microfluidic Irrigation Device for Endodontists

BIOLASE - Good News Across The Board But Still Only Suited For The Most Speculative Investors

Nasdaq Grants BIOLASE 180-Day Extension to Meet Minimum Bid Price Requirement

Third quarter 2021 earnings released: US$0.022 loss per share (vs US$0.21 loss in 3Q 2020)

High number of new directors

Price target increased to US$2.25

Independent Director Garrett Sato has left the company

Independent Director Michael DiTolla has left the company

Second quarter 2021 earnings released: US$0.005 loss per share (vs US$0.12 loss in 2Q 2020)

BIOLASE, Inc. Provides Revenue Guidance for the Third Quarter Ending September 30, 2021

Is BIOLASE (NASDAQ:BIOL) Using Debt Sensibly?

First quarter 2021 earnings released: US$0.055 loss per share (vs US$0.19 loss in 1Q 2020)

BIOLASE, Inc. Provides Revenue Guidance for the Second Quarter of 2021